52North, a Cambridge, UK-based med-tech company focused on urgent care pathways in oncology, raised £4.72M in funding.
The round was led by KHP Ventures, and Cedars-Sinai Intellectual Property Co., with participation from OKG Capital, Cambridge Enterprise Ventures, Cancer Research Horizons, Macmillan Cancer Support, and selected angels including biotech entrepreneur Jonathan Milner and former CEO of Roche Diagnostics Roland Diggelmann.
The company intends to use the funds to advance its products towards market, including the flagship Neutrocheck®, which was granted breakthrough status by the UK Government under its pilot Innovative Devices Access Pathwayearlier this year.
Founded in 2018 by a team of University of Cambridge postgraduates, 52North specializes in oncology-focused med-tech, providing low-cost products to streamline urgent care pathways and enhance patient safety across all socio-economic groups.
The above products are still in development, have not been authorised by regulators and are not currently available for sale.
FinSMEs
06/12/2024